Hyman, Phelps & McNamara Enters its 45th Year Continuing to Expand its Capabilities to Meet Client Needs

Hyman, Phelps & McNamara (HPM) marks its 45th Anniversary year by welcoming three accomplished professionals who reinforce the depth and breadth of the firm’s FDA and DEA practices.

• Naomi Lowy joins HPM as a Principal Drug Regulatory Expert after 18 years at the FDA’s Center for Drug Evaluation and Research (CDER), most recently as the Deputy Director, Division of General Endocrinology. Dr. Lowy previously served as the Deputy Director, Division of Anesthesiology, Addition and Pain Medicine and the Associate Director for Regulatory Science, Office of Drug Evaluation 1, CDER.
• Andrew Hull rejoins the firm as a Director after 6 years as an Assistant United States Attorney in the Western District of Michigan.
• Julie Kim joins the firm as an Associate.

“In 1980, we set out to create a world-class law firm focused on FDA, and 45 years later, Naomi, Andrew and Julie continue that tradition,” said HPM founder Paul Hyman.

“Naomi’s insights and experience will solidify an already strong team of lawyers and regulatory experts helping our clients navigate the drug approval process,” noted Director James Valentine.  “We are excited by Naomi’s strong passion for solving complex regulatory issues and ensuring patient stakeholders have a voice in the drug development process.” For nearly two decades, Dr. Lowy provided leadership across a range of important therapeutic areas, including general endocrinology, pain/opioids, cardiology, neurology, and psychiatry. In her distinguished FDA career, Dr. Lowy provided thought leadership in drug policy and product development for rare endocrinologic diseases, opioids, sarcopenia, and cancer cachexia. She also has extensive experience in advisory committee preparation, authored numerous Guidances for Industry, and co-developed the current drug review process and template.

Andrew Hull brings his expertise to the firm’s enforcement, compliance, and litigation practice. Director Karla L. Palmer, commented.  “Andrew was a highly skilled, tenacious, and sought-after associate at the firm, working on DEA regulatory and litigation matters as well as internal investigations involving FDA-regulated products.  We were sad when he left to gain valued experience as a federal prosecutor but are absolutely thrilled and honored to welcome him back.”  Andrew draws on his government experience investigating and prosecuting violations of the FDC Act, the Controlled Substances Act, the False Claims Act, and other federal healthcare laws to now represent clients facing those issues.

Julie Kim’s 2022 law school graduation year belies her experience.  Julie joins HPM after working at an intellectual property law firm, where she prosecuted and counseled clients on patent portfolios in the medical device and biotechnology sectors.  During law school, Julie obtained practical litigation and transactional experience.  Before her legal career, Julie worked as a nurse practitioner specializing in neurosurgery and infectious diseases.  “Julie brings the type of energy and commitment to projects that has made HPM successful.  We look forward to her development and future success here,” said HPM Managing Director J.P. Ellison.